Ploysongsang S, Aron B S, Shehata W M, Jazy F K, Scott R M, Ho P Y, Morand T M
Urology. 1986 Jan;27(1):10-6. doi: 10.1016/0090-4295(86)90197-4.
One hundred thirty-six patients with adenocarcinoma of the prostate gland Stage A2 (12 patients), Stages B1 and B2 (26), Stage C (64), and Stages D1 and D2 (34 patients) were evaluated clinically and treated in a similar fashion at three hospitals. Megavoltage radiation therapy units were employed to deliver 4,600-5,000 cGy to the whole pelvis, and the prostatic area was treated for an additional 2,000 cGy (boost). Local recurrence was infrequent (8/136 = 6%), and the five-year actuarial survival and disease-free survival rates were 85 and 42 per cent, respectively. Adverse clinical parameters included poor histologic differentiation, age younger than sixty years, and diagnosis by transurethral resection of the prostate rather than needle biopsy in Stage C patients. Severe acute reactions occurred in only 2 patients, and only 2 patients were hospitalized for severe chronic (late) reactions. Whole pelvis radiation yielded a statistically significant improved five-year survival and three-year disease-free survival for similarly evaluated patients for Stage C but not for Stages A and B when compared with 116 patients treated with small-volume radiation (prostate area), previously reported from these three hospitals.
136例前列腺腺癌患者，A2期（12例）、B1和B2期（26例）、C期（64例）以及D1和D2期（34例），在三家医院接受了临床评估并以相似方式进行治疗。采用兆伏级放射治疗设备对整个骨盆给予4600 - 5000厘戈瑞的剂量，前列腺区域再追加2000厘戈瑞（增强剂量）。局部复发很少见（8/136 = 6%），五年精算生存率和无病生存率分别为85%和42%。不良临床参数包括组织学分化差、年龄小于60岁以及C期患者通过经尿道前列腺切除术而非穿刺活检进行诊断。仅2例患者出现严重急性反应，仅2例患者因严重慢性（晚期）反应住院。与这三家医院之前报道的116例接受小体积放疗（前列腺区域）的患者相比，对于C期患者，全骨盆放疗在五年生存率和三年无病生存率方面有统计学显著改善，但A期和B期患者未出现这种情况。
